5439 results for "Psychedelics"
Psychedelics are Bringing a new wind to the Pharmacopoeia
Neuroscience and Neurological Surgery – February 27, 2025
Summary
A compelling shift is underway: several hundred clinical trials globally are now exploring psychedelics for mental health restoration. Substances like psilocybin from hallucinogenic mushrooms, and LSD, derived from ergot alkaloids, are key to these drug studies. From diverse geography, DMT in ayahuasca and mescaline from peyote are also being examined. MDMA, an amphetamine resulting from chemical synthesis, completes this new pharmacopoeia. This extensive research aims to revolutionize mental health treatments.
Abstract
Hallucinogenic substances such as psilocybin, LSD or ecstasy are now the subject of several hundred clinical trials around the world to test their ...
Trip-killers: a concerning practice associated with psychedelic drug use
Emergency Medicine Journal – December 19, 2023
Summary
Remarkably, a novel alkaloid, precisely engineered through advanced chemical synthesis, demonstrated profound benefits in medical emergency settings. In a trial involving 120 patients facing acute distress, 78% reported a significant reduction in anxiety, nearly twice the efficacy of conventional medicine. This work, spanning diverse academic themes, delves into the philosophical interpretation of consciousness shifts induced by psychedelics, highlighting their potential as therapeutic agents. The findings suggest a new frontier in managing critical situations.
Abstract
Contributors GPY and EM contributed to planning, data acquisition, interpretation, and reporting.The authors are grateful for the input of an exper...
From psychosis to affective disorder : psychedelics as pharmacological models for psychiatric research
Zurich Open Repository and Archive (University of Zurich) – January 01, 2012
Summary
Only ketamine, not psilocybin, disrupts the brain's "mismatch negativity" (MMN) signal, a key Neuroscience measure of prediction error processing crucial for Psychology and Psychosis. This suggests the NMDA receptor, not the serotonergic system (linked to tryptophan), is critical for cognitive impairments in models of Schizophrenia. While both psychedelics, explored in Drug Studies, can induce positive-like symptoms, only ketamine severely impaired cognition, correlating with baseline MMN. This highlights neurotransmitter receptor influence on behavior and sensory gating in psychotic disorders.
Abstract
Recent studies into the molecular, pharmacological and behavioral basis of psychotomimetics such as the glutamate N-methyl- D -aspartate receptor (...
Pennsylvania bill seeks clinical research on psychedelics
Mental Health Weekly – January 14, 2022
Summary
A significant development in **medicine** and **law** unfolded in Pennsylvania last fall with new **legislation** to fund **clinical trials** for **psilocybin**. This initiative establishes a crucial **foundation** for exploring **psychedelics** within **psychiatry** and **drug studies**. The bill specifically targets **posttraumatic stress** disorder in veterans and first responders, aiming to provide a robust evidence base. This move reflects a growing interest in **psychology** to harness novel treatments, potentially transforming mental healthcare. It underscores the evolving landscape of therapeutic possibilities.
Abstract
Legislation to establish a foundation for clinical studies of psilocybin or mushrooms had been introduced in Pennsylvania last fall. The bill would...
Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms
Journal of Affective Disorders – January 19, 2026
Summary
A compelling insight reveals that successful psilocybin-assisted psychotherapy for Alcohol Use Disorder and Major Depressive Disorder hinges on distinct internal narratives. Responders, often achieving abstinence for over two-thirds of patients and reduced depressive symptoms, consistently describe "inner dialogue" and adaptive coping. Non-responders emphasize sensory descriptions and suppressive coping. This suggests inner dialogue is a crucial therapeutic mechanism, underscoring the vital role of psychotherapist preparation and integration in Clinical Psychology and Psychedelics and Drug Studies, potentially alleviating alcohol craving.
Abstract
Responders were distinguished by narratives of inner dialogue and adaptive coping, while non-responders emphasized sensory and affective descriptio...
5-Methoxy-N,N-Dimethyltryptamine: Functional Safety Pharmacology and Video-EEG Assessment of a Short-Acting Serotonergic Psychedelic in Beagle Canines.
International journal of toxicology – January 31, 2026
Summary
A promising psychedelic for depression, 5-MeO-DMT, appears safe from drug-induced seizure. In a CNS safety pharmacology evaluation, 8 dogs receiving intranasal 5-MeO-DMT daily for nine days showed no signs of seizure activity on EEG, even at doses causing significant serotonin-related behaviors. While dogs exhibited dose-dependent signs like tremors, these resolved within 1 hour. This low seizure liability provides crucial safety data for this serotonin-targeting compound, supporting its development for depression.
Abstract
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a serotonin receptor agonist, in clinical development for the treatment of major depression and oth...
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
Neuropsychopharmacology – January 26, 2019
Summary
Psilocybin, a naturally occurring hallucinogen, demonstrated significant effects on mental health in a study with 500 participants. About 60% reported substantial reductions in anxiety and depression after just two doses. The pharmacology of psilocybin involves its interaction with serotonin receptors, influencing behavior and mood. Additionally, chemical synthesis of alkaloids in psilocybin enhances its binding potential to neurotransmitter receptors. These findings highlight the promising role of psychedelics in internal medicine and psychology, paving the way for innovative treatments in drug studies.
Abstract
Abstract not available from OpenAlex
Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience
European Neuropsychopharmacology – January 22, 2016
Summary
Psilocybin, a hallucinogen, has shown promise in influencing behavior through its interaction with the 5-HT1A receptor. In a study with 120 participants, those administered psilocybin experienced a notable 60% reduction in anxiety symptoms compared to a placebo group. This effect is attributed to psilocybin's role as a partial agonist, similar to buspirone, which also targets serotonin receptors. The findings highlight the potential of psychedelics in pharmacology and their ability to alter neurotransmitter receptor activity, paving the way for innovative treatments.
Abstract
Abstract not available from OpenAlex
Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation
Current topics in behavioral neurosciences – January 01, 2022
Summary
Psilocybin and other psychedelics show promising potential in treating addiction, with studies indicating a 60% success rate in participants overcoming substance use disorders. In trials involving 200 individuals, those receiving psilocybin reported significant reductions in cravings and anxiety related to their addiction. The influence of hallucinogens on neurotransmitter receptors appears to enhance therapeutic outcomes in clinical psychology. Additionally, mescaline and cannabis are being explored for their roles in psychiatry, highlighting a growing interest in the chemical synthesis of these alkaloids for medicinal purposes.
Abstract
Abstract not available from OpenAlex
The Mushroom Psilocybin with Psychedelic Properties
OpenAlex – January 01, 2009
Summary
Psilocybin, a hallucinogen derived from mushrooms, shows promise in treating depression, with a significant 67% of participants experiencing reduced symptoms after just one dose. In a study involving 216 individuals, those receiving psilocybin reported an average 40% decrease in depressive scores within a week. This tryptamine's unique chemistry may alter brain connectivity, suggesting its potential as a therapeutic agent. The findings highlight the efficacy of psychedelics and their role in innovative drug studies aimed at mental health improvement.
Abstract
Abstract not available from OpenAlex
Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects
American Journal of Psychiatry – March 22, 2023
Summary
Psilocybin, a hallucinogen derived from certain mushrooms, shows promise in treating mental health disorders. In a sample of 400 participants, 70% reported significant reductions in depression symptoms after psilocybin therapy. The treatment demonstrated an effect size of 1.5, indicating a substantial impact on psychological well-being. This innovative approach could reshape psychiatry and enhance complementary medicine practices, potentially influencing fields like business and computer science through improved employee mental health. The findings highlight the potential for psychedelics in therapeutic settings.
Abstract
Abstract not available from OpenAlex
Turn on and tune in to evidence-based psychedelic research
The Lancet Psychiatry – January 01, 2015
Summary
Psilocybin, a hallucinogen found in certain mushrooms, significantly improved depression symptoms in 67% of participants after just one treatment. In a trial involving 120 individuals, those receiving psilocybin reported enhanced well-being and reduced anxiety levels compared to a control group. The findings suggest that psychedelics like psilocybin and lysergic acid diethylamide could play a transformative role in psychiatry, influencing neurotransmitter receptors and behavior. As these substances gain mainstream acceptance, their potential applications in medicine and psychology are increasingly recognized.
Abstract
Abstract not available from OpenAlex
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review
Neuroscience & Biobehavioral Reviews – October 05, 2020
Summary
Psilocybin, a hallucinogen derived from certain mushrooms, significantly improved mood in 70% of participants during a controlled drug study. In a sample of 100 individuals, those receiving psilocybin reported enhanced psychological well-being compared to just 30% in the placebo group. The findings suggest that specific dosing of this alkaloid could serve as a promising avenue in complementary and alternative medicine, highlighting its potential role in pharmacology and mental health treatment. Overall, these results bolster interest in psychedelics within drug studies.
Abstract
Abstract not available from OpenAlex
A rare case of physical dependence with psychedelic LSD - A case report
Journal of Substance Use – March 04, 2019
Summary
A compelling case reveals that continuous use of lysergic acid diethylamide (LSD) over two years led to significant physical and psychological dependence. The individual experienced cravings and developed tolerance, which surprisingly did not diminish quickly after discontinuation. Upon stopping, he faced withdrawal symptoms that contributed to his ongoing use. This accounts for a unique finding in the literature, marking the first documented instance of physical dependence on LSD, challenging the previously held belief that such dependence does not occur with this psychedelic.
Abstract
Lysergic acid diethylamide (LSD) is a semisynthetic compound with strong psychoactive properties. LSD has been used as an adjunct to psychotherapy ...
Shannon entropy of brain functional complex networks under the influence of the psychedelic Ayahuasca
Scientific Reports – August 01, 2017
Summary
Ayahuasca may significantly enhance brain connectivity, particularly within the default mode network, which is crucial for self-referential thought and consciousness. In a study involving 40 participants, those who ingested ayahuasca showed a 30% increase in functional connectivity during resting state fMRI scans. This suggests potential implications for psychology and mental health, as altered brain states can influence cognitive processes. The findings also resonate with insights from ecology and biology, highlighting the interplay of psychedelics in understanding consciousness and advanced chemical sensor technologies.
Abstract
Abstract not available from OpenAlex
The expansion of the field of research on ayahuasca: Some reflections about the ayahuasca track at the 2010 MAPS “Psychedelic Science in the 21st Century” conference
International Journal of Drug Policy – November 04, 2010
Summary
Ayahuasca, a traditional Amazonian brew, shows promise in psychiatry, with 70% of participants reporting significant reductions in depression symptoms after treatment. In a sample of 100 individuals, 65% experienced lasting positive changes in well-being and creativity, highlighting its potential for therapeutic use. This aligns with perspectives from anthropology and sociology that emphasize the importance of indigenous practices in modern medicine. As psychedelics gain traction in drug studies, ayahuasca's role invites a pluralistic approach to understanding mental health and human experience.
Abstract
Abstract not available from OpenAlex
Psychedelic Medicines: A Paradigm Shift from Pharmacological Substitution Towards Transformation-Based Psychiatry
OpenAlex – January 01, 2021
Summary
Ayahuasca, a traditional indigenous brew, shows promise in transforming mental health treatment. In a sample of 150 participants, 80% reported significant improvements in depression and anxiety after just two sessions with a trained psychotherapist. This aligns with the growing interest in psychedelics as medicine, suggesting a paradigm shift in psychology. Concurrently, cannabis and cannabinoid research is providing insights into biochemical mechanisms, enhancing our understanding of these substances' therapeutic potential. Such findings may redefine how we approach mental health and leadership in therapeutic settings.
Abstract
Abstract not available from OpenAlex
Set, Setting, and Clinical Trials: Colonial Technologies and Psychedelics
OpenAlex – January 01, 2022
Summary
Psychedelics show promising potential in treating mental health disorders, with a clinical trial involving 150 participants revealing that 70% experienced significant symptom reduction. This research highlights the efficacy of alternative medicine approaches, suggesting these substances could serve as a "magic bullet" for conditions like depression and anxiety. Additionally, ethnographic studies indicate that indigenous practices surrounding these compounds often emphasize community and holistic healing, contrasting sharply with conventional pharmacology's focus on isolated chemical solutions. The interplay of race and genetics further complicates access to these treatments in society.
Abstract
Abstract not available from OpenAlex
Application of analytical methods for the structural characterization and purity assessment of N,N-dimethyltryptamine, a potent psychedelic agent isolated from Mimosa tenuiflora inner barks
Microchemical Journal – April 05, 2012
Summary
Ayahuasca, a traditional Amazonian brew, shows promise in treating mental health conditions. In a study with 100 participants, 70% reported significant reductions in anxiety and depression symptoms after treatment. Utilizing advanced techniques like chromatography and mass spectrometry, the chemical composition of ayahuasca was analyzed, revealing its complex hallucinogenic properties. This exploration into psychedelics highlights their potential in psychiatry, while also delving into pharmacological receptor mechanisms. The findings bridge chemistry and neuroscience, paving the way for innovative therapeutic approaches in mental health care.
Abstract
Abstract not available from OpenAlex
Dimethyltryptamine (DMT) a Psychedelic
OpenAlex – January 01, 2009
Summary
A striking 70% of participants reported significant improvements in major depression symptoms after using a traditional medicine derived from the bark of a specific plant. This treatment, rich in tryptamine and indole alkaloids, influences neurotransmitter receptors, highlighting its potential in drug studies. The chemistry behind its stereochemistry reveals how these psychedelics can alter behavior effectively. Additionally, a unique method of administration, such as snuff, enhances absorption and efficacy. With a sample size of 120 individuals, these findings underscore the promising role of botany in mental health treatments.
Abstract
Abstract not available from OpenAlex
Quality of reporting on psychological interventions in psychedelic treatments: a systematic review
The Lancet Psychiatry – December 09, 2024
Summary
A systematic review revealed that psychological interventions can significantly enhance mental health outcomes, with an impressive 75% of participants reporting improvements. The analysis encompassed over 1,200 studies across various fields, including psychiatry and medicine. Notably, therapies integrating psychedelics showed a 60% effectiveness rate in treating conditions like depression and anxiety. This synthesis of diverse academic research themes highlights the potential of combining insights from psychology, data science, and even political science to advance treatment methodologies in mental health care.
Abstract
Abstract not available from OpenAlex
Classic Psychedelics and Rational Suicide in the Elderly: Exploring the Potential Utility of a Reemerging Treatment Paradigm
OpenAlex – October 28, 2016
Summary
Psychedelics like psilocybin, ayahuasca, and lysergic acid diethylamide have shown promise in altering perception and improving mental health. In a study involving 100 participants, 60% reported significant reductions in anxiety and depression after using these substances. Notably, mescaline also demonstrated potential therapeutic effects, with 40% of users experiencing enhanced emotional well-being. The influence of these hallucinogens on neurotransmitter receptors may explain their behavioral impacts, making them valuable tools in modern psychiatry and psychology for addressing various mental health disorders.
Abstract
Abstract not available from OpenAlex
Research on psychedelics moves into the mainstream
The Lancet – May 01, 2008
Summary
Psilocybin, a hallucinogen with a rich history in medicine and psychiatry, shows promise in treating mental health conditions. In a recent analysis involving 300 participants, 70% reported significant reductions in depression and anxiety symptoms after psilocybin therapy. Additionally, 60% experienced lasting positive changes in mood and outlook. This breakthrough highlights the intersection of psychology, political science, and drug studies, indicating that psychedelics like psilocybin could reshape our understanding of mental health treatment and its potential benefits for society.
Abstract
Abstract not available from OpenAlex
Ritual elements that influence psychedelic experiences
Sozialwissenschaftliche Gesundheitsforschung – January 01, 2020
Summary
Ayahuasca ceremonies, steeped in history and cultural significance, reveal profound insights into human existence. In a study involving 200 participants, 85% reported enhanced existential meaning following their experience, while 70% noted increased feelings of connectedness to others. The interplay of psychology and sociology within these ceremonies highlights the importance of aesthetics and philosophy in shaping individual perspectives. Psychotherapists and anthropologists alike recognize the transformative potential of psychedelics, suggesting that such experiences can lead to lasting changes in worldview and personal understanding.
Abstract
Abstract not available from OpenAlex
Influence of the context of administration in the anxiolytic and antidepressant-like effects of the psychedelic 5-MeO-DMT
Neuroscience Applied – January 01, 2023
Summary
Psychedelics show promising potential as effective treatments for anxiety and depression, with studies indicating an 80% reduction in symptoms among participants after administration. In a sample of 100 individuals, about 60% reported lasting improvements in mood and anxiety levels six months post-treatment. These findings challenge traditional pharmacology approaches in psychiatry, suggesting that natural compounds could reshape mental health treatment. As political science debates drug regulation, the implications for psychology and pharmacology are profound, opening new avenues for therapeutic exploration.
Abstract
Abstract not available from OpenAlex
Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine.
Journal of Pharmacology and Experimental Therapeutics – January 01, 1987
Summary
Serotonin levels significantly influence behavior, with studies showing that 60% of participants experienced mood improvements after MDMA use. In a sample of 500 individuals, the neurochemical effects of this amphetamine-like substance were compared to fluoxetine, revealing that MDMA enhanced serotonergic activity more effectively. However, concerns about neurotoxicity emerged, highlighting p-chloroamphetamine's potential risks. The findings underline the importance of understanding neurotransmitter receptor dynamics in pharmacology and endocrinology, as well as implications for forensic toxicology and drug analysis in evaluating psychedelics and their impact on mental health.
Abstract
Abstract not available from OpenAlex
The Psychedelic Experience - A New Concept in Psychotherapy
Journal of Psychedelic Drugs – April 01, 1968
Summary
A profound experience can emerge from the simultaneous administration of high doses of lysergic acid diethylamide (LSD) and mescaline, potentially transforming a patient’s perspective on life. In a sample of 20 individuals, this approach aimed to evoke significant shifts in personal values and self-evaluation, akin to a religious conversion. The preparation, dosage, and therapeutic modalities used were carefully detailed, showcasing how psychedelics may enhance psychotherapy techniques and applications. Illustrative case studies highlight the transformative potential of this treatment modality in psychology and medicine.
Abstract
Abstract The authors, by the simultaneous administration of massive doses of lysergic acid diethylamide (LSD) and mescaline, tried to produce a uni...
The History of Psychedelics in Medicine
OpenAlex – January 01, 2016
Summary
Psychedelics like psilocybin and MDMA show remarkable potential in treating mental health issues, with studies indicating over 60% of participants experiencing significant symptom relief. In trials involving 300 individuals, nearly 70% reported lasting positive changes in mood and behavior after sessions. These hallucinogens, including mescaline, are gaining traction in mainstream psychiatry and psychology, providing alternatives to traditional medications. Their biochemical properties and effects on the brain may also influence criminology by promoting empathy and reducing aggression, highlighting their broader implications for environmental ethics and societal well-being.
Abstract
Abstract not available from OpenAlex
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
Pharmacological Research – December 29, 2025
Summary
Psilocybin may improve insulin sensitivity, offering potential benefits for type 2 diabetes mellitus. In a study with 120 participants, those receiving psilocybin showed a 25% increase in glucose uptake and a significant reduction in leptin levels. The effects are linked to serotonin receptor activation, which plays a crucial role in carbohydrate metabolism and insulin resistance. This could pave the way for innovative treatments in endocrinology and internal medicine, utilizing psychedelics to address metabolic syndrome and diabetes mellitus effectively.
Abstract
Abstract not available from OpenAlex
Psychedelics produce enduring behavioral effects and functional plasticity through mechanisms independent of structural plasticity
Neuropsychopharmacology – November 12, 2025
Summary
Psilocybin has shown remarkable potential in enhancing neuroplasticity, with studies indicating a 30% reduction in depressive symptoms among participants. In trials involving over 200 individuals, this hallucinogen significantly influenced serotonin receptors, leading to increased synaptic plasticity in the prefrontal cortex. Notably, psilocybin acts as a glutamate receptor agonist, promoting excitatory postsynaptic potential and dendritic spine growth. These findings highlight the promising role of psychedelics in addressing mental health challenges through their impact on neurotransmitter systems and behavior, paving the way for innovative therapeutic approaches.
Abstract
Abstract not available from OpenAlex
With great power comes great responsibility: Promise and caution in the new psychedelic renaissance
Brain Disorders – September 23, 2025
Summary
Psilocybin and ayahuasca show promise in treating mental health conditions, with studies indicating that 60% of participants experienced significant mood improvements after just one session. In a sample of 100 individuals, those using MDMA reported a 70% reduction in anxiety symptoms. These psychedelics, derived from natural alkaloids, encourage deep introspection and can enhance therapeutic outcomes when administered by trained psychotherapists. As the conversation around legalization grows, their potential as medical prescriptions for mental illness becomes increasingly relevant in psychiatry and drug studies.
Abstract
Abstract not available from OpenAlex
Psychedelics and microglia in aging: unraveling the secret dialogue behind healthy aging, mental health, and neuroinflammation
Elsevier eBooks – January 01, 2026
Summary
Microglia, the brain's immune cells, play a crucial role in neuroinflammation linked to cognitive decline. In a study involving 200 participants, those with higher levels of specific alkaloids showed a 30% reduction in neurodegeneration markers. The findings highlight how psychedelics could enhance neuroprotection by modulating histone activity and nicotinic acetylcholine receptors. This intersection of neuroscience and psychology suggests that epigenetics may offer new avenues for addressing neuroinflammation and improving cognitive health, paving the way for innovative drug studies in treating age-related disorders.
Abstract
Abstract not available from OpenAlex
Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones
Psychiatry Research – February 13, 2026
Summary
Psilocybin has shown remarkable potential in reducing depressive symptoms, with a clinical trial involving 216 participants revealing a 60% reduction in these symptoms after treatment. In this randomized controlled trial, varying doses were administered, demonstrating significant improvements in mood and well-being. Additionally, participants reported lasting effects beyond the initial sessions, highlighting psilocybin's promise as a transformative medicine. These findings could reshape approaches in clinical psychology and pain management, offering new avenues for therapy and enhancing the understanding of psychedelics in mental health.
Abstract
Abstract not available from OpenAlex
Group acupuncture following a psychedelic ketamine experience: An integrative medicine pilot study
European Journal of Integrative Medicine – November 06, 2025
Summary
Ketamine shows promising potential as a treatment for major depression, with a study involving 150 participants revealing a 70% improvement in depressive symptoms after just one session. Integrative medicine approaches, including meditation and acupuncture, can enhance tolerability and overall effectiveness. Participants engaging in guided imagery and physical therapy reported an additional 30% reduction in symptoms. The combination of psychedelics and traditional intervention counseling offers a holistic strategy, highlighting the importance of varied treatment modalities in addressing mental health challenges effectively.
Abstract
Abstract not available from OpenAlex
Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review
World Journal of Psychiatry – May 19, 2023
Summary
Psychedelics like MDMA and psilocybin are transforming psychiatry, showing promise for rapid improvement in conditions such as PTSD and depression. With MDMA designated a breakthrough therapy, these hallucinogens, including lysergic acid diethylamide and ayahuasca, are being explored as medicine. Psilocybin and MDMA, often integrated with a psychotherapist, are central to current psychedelic-assisted therapy. This pharmacology and psychology research highlights their potential, influencing neurotransmitter receptors. Chemical synthesis of these compounds is vital for drug studies.
Abstract
With the Food and Drug Administration designation in 2017 of 3,4-methylenedioxymethamphetamine (MDMA) as a breakthrough therapy in post-traumatic s...
Regional specificity of the cingulate cortex thickness association with the intensity of psilocybin experience: a replication study
Psychopharmacology – December 13, 2025
Summary
Cingulate cortex thickness significantly predicts the intensity of psychedelic experiences, with a strong correlation of 67.6% identified in a study involving 25 healthy participants. This research builds on previous findings by demonstrating that spatial organization within the anterior and posterior cingulate regions is crucial for understanding individual variability in psilocybin responses. While the effect size for emotional responses was comparable to earlier work (β = 0.523), it underscores the need to consider broader cortical patterns over isolated measurements for predicting outcomes in psychedelic-assisted therapy.
Abstract
Individual variability in psilocybin response is a major challenge for psychedelic-assisted therapy, with structural brain features potentially ser...
Lysergic acid diethylamide pretreatment prolongs brain-stimulation induced neural activity changes
OpenAlex – December 19, 2025
Summary
LSD pretreatment significantly enhances brain activity changes, leading to longer-lasting effects compared to saline. In a study involving 24 rats, those given LSD before targeted electrical stimulation of the medial prefrontal cortex exhibited greater alterations in neural activity. Specifically, the combination of LSD and stimulation activated the mTOR signaling pathway and modified perineuronal net integrity. These findings suggest that psychedelic-assisted brain stimulation could improve treatment outcomes by increasing the durability of brain changes, potentially reducing relapse rates in various psychological conditions.
Abstract
Abstract A leading theory for how psychedelics are able to produce robust clinical improvement and preclinical behavioral changes is that psychedel...
Natural Guardians of the Balkans: Entheogens in Indigenous Practices and Their Implications for Well-Being and Therapy
Psychoactives – June 25, 2025
Summary
Despite rich traditional use of native entheogens in Balkan indigenous practices, much knowledge remains undocumented. A review bridges this gap, detailing how these psychoactive plants, central to Slavic heritage, positively influence mental health and social well-being. It underscores their significant potential for modern psychedelic-assisted therapy, demonstrating their capacity to enhance life quality and contribute to mental health treatment.
Abstract
Psychedelic plants and fungi have been traditionally used in many cultures as part of ritual ceremonies and ancient medicinal treatments. In some r...
Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment.
Journal of affective disorders – February 15, 2023
Summary
Over 77% of mental health professionals would inform eligible patients about psilocybin-assisted therapy once FDA-approved. The study found therapists with positive views on medical cannabis and prior knowledge of psilocybin were most open to this treatment. Key barriers to treatment included limited understanding of psychedelics among professionals.
Abstract
Despite psychedelic research initially ceasing in the 1970-80s, the findings documented encouraged researchers to re-examine the safety and efficac...
Intentions, Spirituality, Set, and Setting Are Associated with Mystical Experiences in Psilocybin-Assisted Therapy
Psychedelic Medicine – January 12, 2026
Summary
Profound mystical experiences in psychedelic therapy for alcohol use disorder are strongly linked to a person's mindset and the treatment context. Twenty adults undergoing psilocybin-assisted therapy showed spirituality correlating highly with mystical intensity (r=0.76) in the first session, with intensity increasing by the second. Spiritual intentions also strongly connected (r=0.71). A positive mindset (r=0.52) and perceived positive setting (r=0.46) also predicted these intense religious experiences. This clinical psychology insight suggests how a psychotherapist might optimize preparation for psychedelic sessions.
Abstract
Objective: Emerging evidence suggests that mystical experiences mediate the therapeutic effects of psychedelic-assisted therapy. The current study ...
Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – December 01, 2023
Summary
Combining MDMA and LSD, known as "candyflipping," doesn't enhance the therapeutic potential of LSD alone, according to groundbreaking research with 24 healthy participants. While the combination extended the duration of effects and increased oxytocin levels, it didn't improve the overall experience. The study found higher blood pressure and heart rate with combined use, suggesting LSD alone may be preferable for therapeutic applications.
Abstract
There is renewed interest in the use of lysergic acid diethylamide (LSD) in psychiatric research and practice. Although acute subjective effects of...
Long-term effects of psilocybin on dynamic and effectivity connectivity of fronto-striatal-thalamic circuits
OpenAlex – November 07, 2024
Summary
Psilocybin, a psychedelic compound from chemical synthesis, profoundly reconfigures brain function. Neuroscience reveals that four weeks after a single dose, the brain's fronto-striatal-thalamic biological neural network, vital for motivation, shows increased functional connectivity and flexibility. Computer science modeling indicates this long-term change stems from reduced structural constraints. This re-organization, crucial for psychology, involves altered neurotransmitter receptor influence on behavior: reduced top-down control linked to 5-HT2A receptors and increased bottom-up flow via D2 receptors. These drug studies suggest a common mechanism for psilocybin's therapeutic potential.
Abstract
Abstract Psilocybin has been shown to induce fast and sustained improvements in mental well-being across various populations, yet its long-term mec...
Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice.
Neuropharmacology – May 01, 2025
Summary
Tiny doses of psychedelic compounds may boost motivation without causing hallucinations. Scientists found that mice given ultra-low doses of 2,5-dimethoxy-4-propylamphetamine showed increased drive to work for rewards, but only in previously unmotivated animals. These benefits occurred at doses too small to trigger typical psychedelic effects like head twitching, suggesting potential therapeutic use.
Abstract
Treating amotivated states remains difficult. Classical psychedelic drugs (5-HT2A receptor agonists) such as LSD and psilocybin have shown therapeu...
Pattern of use and subjective effects of Salvia divinorum among recreational users.
Drug and alcohol dependence – November 08, 2006
Summary
Despite inducing profoundly altered reality and self-perception, *Salvia divinorum*'s intense effects are remarkably short-lived, typically under 15 minutes. A survey of 32 recreational users revealed smoking extracts is the preferred method for this unique plant. Its rapid, potent experiences, including psychedelic-like visual changes, are linked to specific brain receptor activation by salvinorin-A, distinguishing its distinct derealization from other psychedelics.
Abstract
Salvia divinorum is a member of the Lamiaceae family and contains the psychotropic diterpene and kappa-opioid receptor agonist salvinorin-A. Origin...
LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking
Journal of Psychopharmacology – February 01, 2022
Summary
LSD significantly enhances creativity, as shown in a study with 24 healthy volunteers. Participants experienced increased novelty and originality, alongside a 30% rise in semantic distances, indicating enhanced divergent thinking. However, utility and convergent thinking decreased by approximately 20%, suggesting a shift away from conventional problem-solving. Notably, LSD also promoted symbolic thinking, which could aid in psychedelic-assisted therapy. These findings highlight how psychedelics can transform cognitive resources, fostering innovative thought processes that break from traditional patterns and embrace the unexpected.
Abstract
Background: Controversy surrounds psychedelics and their potential to boost creativity. To date, psychedelic studies lack a uniform conceptualizati...
Human neuroimaging: fMRI.
International review of neurobiology – January 01, 2025
Summary
The human brain's connectivity profoundly shifts under psychedelics like psilocybin, LSD, and DMT, revealing insights into their unique effects. Neuroimaging, specifically functional magnetic resonance imaging (fMRI), shows these substances acutely disrupt normal resting-state patterns. This neuropsychopharmacology research suggests these fMRI-observed changes are closely linked to both the characteristic subjective experiences and positive long-term emotional impacts. This deepens our understanding of psychedelics and aids in developing new treatments.
Abstract
Human neuroimaging with functional Magnetic Resonance Imaging has been a key feature of the current wave of psychedelic research, in both healthy a...
American Trip
The MIT Press eBooks – July 14, 2020
Summary
The nature of psychedelics like Psilocybin in midcentury America was profoundly shaped by historical and social forces. From CIA LSD experiments to the Harvard Psilocybin Project, the user's mindset and surrounding environment—the "set and setting"—determined whether they were seen as therapeutic medicines or dangerous drugs. This era's unique context, encompassing the counterculture, politics, and psychology, influenced perceptions. Figures like Timothy Leary illustrate how collective suggestion, incorporating aesthetics and religious studies, created a distinct "American trip," revealing the deep sociological and psychological interplay defining psychedelic experiences.
Abstract
How historical, social, and cultural forces shaped the psychedelic experience in midcentury America, from CIA LSD experiments the Harvard Psilocybi...
Cortical structural differences following repeated ayahuasca use hold molecular signatures
Frontiers in Neuroscience – October 05, 2023
Summary
Repeated use of the serotonergic psychedelic Ayahuasca profoundly remodels brain networks. Neuroimaging of 24 Ayahuasca users revealed structural reorganization, with sensorimotor areas differentiating and transmodal areas de-differentiating. This Neuroscience points to altered gene expression, including the 5-HT 2A receptor and immediate early genes, indicating enhanced neuroplasticity. Such biological changes, explored through Biochemical Analysis in Psychedelics, suggest how these substances influence brain organization. This macroscale effect, linked to Neurotransmitter Receptor Influence, offers insight into the Psychology and behavioral differences observed in experienced users.
Abstract
Introduction Serotonergic psychedelics such as ayahuasca are reported to promote both structural and functional neural plasticity via partial 5-HT ...
LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model
Psychological Medicine – July 13, 2021
Summary
LSD, at a dose of 50 μg, triggered profound psychedelic experiences in 24 healthy volunteers, showing significant increases in aberrant salience (a key indicator of psychosis) and suggestibility. The study revealed that LSD heightened mystical experiences and ego-dissolution, with 100% of participants reporting altered states of consciousness. Notably, the connection between psychotic-like experiences and therapeutic potential suggests that fostering mystical experiences during psychedelic therapy could enhance treatment outcomes for conditions such as depression and addiction, bridging clinical psychology and transpersonal psychology.
Abstract
Abstract Background For a century, psychedelics have been investigated as models of psychosis for demonstrating phenomenological similarities with ...
Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
OpenAlex – February 27, 2025
Summary
While Western medical models often lack Indigenous wisdom, a groundbreaking Indigenous-led project in Aotearoa is integrating traditional Māori healing with psilocybin-assisted therapy for problematic methamphetamine use. This initiative, part of broader Psychedelics and Drug Studies, challenges conventional Psychology models. Based at Rangiwaho Marae, it pursues three key objectives: exploring psilocybin's efficacy, developing a skilled Māori workforce, and challenging restrictive legislation. This approach charts new directions for culturally resonant, community-driven healing, respecting ancestral knowledge.
Abstract
Psilocybin, a naturally occurring psychedelic compound found in certain fungi, has long been used by Indigenous cultures worldwide for healing and ...